CVC and DSM-Firmenich are reportedly finalising the structure and terms of the transaction, which could be announced in the coming days. DSM-Firmenich is expected to retain a minority stake in the business following completion. The potential sale forms part of DSM-Firmenich's strategy to reduce its exposure to the global vitamins market, which has come under pressure from lower-cost Chinese competitors. The company began exploring options for the animal health unit in 2024 and has been advised by UBS and Piper Sandler. In the first half of 2025, the animal health business generated net sales of '1.8bn, or about $2.1bn, representing a 14% increase compared with the same period a year earlier. DSM-Firmenich previously completed the '1.5bn, or $1.8bn, sale of its stake in the Feed Enzymes Alliance to Novonesis. Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000...
learn more
